With the New Dalriada Partnership, Champignon Expects to Develop a Robust Pipeline of Preclinical and Clinical Assets with Strong IP Protection Dalriada’s Medicinal Chemistry Expertise Combined with Champignon’s Innovative Formulation... read more →
Psychedelics Companies That Own Clinics May Hold the Answer to One of the Top Investor Questions: "How Will Individual Firms Generate Meaningful Revenue?" As We Know, the Business of Biotech... read more →
Surging Investor Demand Continues to Be Concentrated into a Limited Number of Psychedelic Stocks As the Psychedelics Industry Continues to Blossom, the Current Circumstances Have Created a Situation for Investors... read more →
Early Weed Investors and Business Minds are Positioning Themselves in the World of Psychedelic Medicine as the Flow of Smart Money Hits the Market Canopy Growth Founder Bruce Linton and... read more →
Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelic Stock News Stories for the Week of May 11th – 17th, 2020.... read more →
The First Drug in the Psychedelics Space, Ketamine-Based Spravato By J&J Was Approved Last Year At $6,700 a Month, Spravato is Expected to Generate Well North of $1.3 Billion Annually... read more →
Champignon Advances Psychedelic Clinic Expansion Announcing Terms for First U.S. Acquisition of California-Based Wellness Clinic of Orange County Today's News Comes Just One Day After the Psychedelics Company Announced Dr.... read more →
Medical Professionals are Beginning to Use Psychedelics to Treat a Host of Mental Disorders Champignon Brands is Growing a Vertically Integrated Psychedelic Drug Company Other Major Competitors Are Using Different... read more →